Deucrictibant Immediate-release is a small molecule commercialized by Pharvaris, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 7 clinical trials, of which 4 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Deucrictibant Immediate-release’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Deucrictibant Immediate-release is expected to reach an annual total of $38 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Deucrictibant Immediate-release Overview
Deucrictibant (PHVS-416) is under development for the treatment and prevention of hereditary angioedema (HAE). It is administered through oral route in the form of immediate-release (IR) softgel capsule. The drug candidate acts by targeting B2 bradykinin receptor (BDKRB2).
Pharvaris Overview
Pharvaris, is a clinical-stage biopharmaceutical company that develops and commercialization of innovative therapies for rare diseases. The company pipeline includes Deucrictibant (PHA121, PHA-022121) is a novel, small-molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). Pharvaris also evaluating and PHVS416, a soft gel capsule formulation and PHVS719, a tablet formulation for prophylactic treatment of bradykinin-mediated angioedema. The company works in collaboration with pharmaceutical for product development. The company operates in the US, Switzerland and the Netherlands. Pharvaris is headquartered in Leiden, Zuid-Holland, the Netherlands.
The operating loss of the company was EUR96.9 million in FY2023, compared to an operating loss of EUR86.7 million in FY2022. The net loss of the company was EUR100.9 million in FY2023, compared to a net loss of EUR76.3 million in FY2022.
For a complete picture of Deucrictibant Immediate-release’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.